Ondansetron ODT 4 MG tablet 30S
Ended Awarded
- Contract number
- SPE2D325F213T
- Awardee
-
Chartwell RX LLC UEI ER5UA9TYBGH4
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $1,185
Award facts
- Contract value 100% obligated
- $1,184.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Congers, NY 10920, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Defense, through its Medical Supply Chain organization, awarded a delivery order to Chartwell RX LLC on July 14, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This firm fixed-price delivery order, valued at $1,184.50 with an ultimate completion date of July 17, 2025, represents a continuation of the Defense Logistics Agency's pharmaceutical supply chain operations. The award was not designated as a set-aside contract and will be performed at Chartwell RX's facility in Congers, New York. Ondansetron is a critical antiemetic medication widely used in military treatment facilities and government healthcare systems to manage nausea and vomiting in patient populations.
Chartwell RX LLC, a for-profit pharmaceutical company registered in the System for Award Management since April 2019, has established itself as a reliable supplier of generic and branded pharmaceuticals to federal agencies through multiple Indefinite Delivery Vehicle contracts. The company's extensive contract portfolio with the Defense Logistics Agency and Department of Health and Human Services demonstrates its significant role in supporting federal healthcare infrastructure, with previous awards exceeding $200 million for various pharmaceutical products including doxycycline, clarithromycin, and ondansetron formulations. This delivery order exemplifies the company's specialized focus on oral medications and its consistent capacity to fulfill time-sensitive pharmaceutical requirements for defense and military healthcare operations.
Quick answers
Who was awarded contract SPE2D325F213T?
SPE2D325F213T was awarded to Chartwell RX LLC by Medical Supply Chain (Troop Support) on July 14, 2025.
How much is contract SPE2D325F213T worth?
The government has obligated $1,185 on SPE2D325F213T.
Is contract SPE2D325F213T an order under another contract?
Yes. SPE2D325F213T is a delivery order under SPE2D020D0005, an indefinite delivery contract.
Was contract SPE2D325F213T competed?
The extent of competition for SPE2D325F213T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award